Published in Semin Oncol on December 01, 1992
Doxorubicin cardiomyopathy. Cardiology (2009) 1.99
The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev (2008) 1.80
Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol (2013) 1.57
Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics (2011) 1.53
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci (2012) 1.40
Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal (2011) 1.34
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun (2013) 1.31
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology (2009) 1.29
Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol (2009) 1.21
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci U S A (1996) 1.17
Characterization of covalent adriamycin-DNA adducts. Proc Natl Acad Sci U S A (1998) 1.16
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci U S A (1996) 1.11
Manganese superoxide dismutase: beyond life and death. Amino Acids (2010) 1.06
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp Clin Cardiol (2011) 1.05
Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells. Int J Oncol (2007) 1.04
Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res (2010) 1.03
Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab (2013) 1.01
Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-trigged drug release. J Control Release (2011) 1.00
Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis. Cell Death Dis (2015) 0.99
Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clin Cancer Res (2014) 0.98
Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. Oncotarget (2014) 0.98
Effects of cyclic lipodepsipeptide structural modulation on stability, antibacterial activity, and human cell toxicity. ChemMedChem (2012) 0.98
Identification of genes required for protection from doxorubicin by a genome-wide screen in Saccharomyces cerevisiae. Cancer Res (2007) 0.95
Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxid Med Cell Longev (2015) 0.95
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics (2012) 0.94
Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett (2013) 0.93
Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Res (2008) 0.93
Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer. Biomaterials (2012) 0.93
Self-assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancer. Adv Funct Mater (2013) 0.93
Vincristine attenuates doxorubicin cardiotoxicity. Biochem Biophys Res Commun (2008) 0.93
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes. BMC Pharmacol (2009) 0.92
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol (2012) 0.91
Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int (2012) 0.91
Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest (1995) 0.91
First Total Synthesis of the Potent Anticancer Natural Product Dideoxypetrosynol A: Preparation of the "Skipped" (Z)-Enediyne Moiety by Oxidative Coupling of Homopropargyl Phosphonium Ylide. European J Org Chem (2008) 0.90
Stability of adriamycin-induced DNA adducts and interstrand crosslinks. Nucleic Acids Res (1995) 0.90
Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) (2010) 0.90
Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Res (2000) 0.89
CDK5RAP2 is required for spindle checkpoint function. Cell Cycle (2009) 0.88
Formation of adriamycin--DNA adducts in vitro. Nucleic Acids Res (1994) 0.88
Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol (2010) 0.87
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C. BMC Cancer (2012) 0.86
Impact of breast cancer and combination chemotherapy on oxidative stress, hepatic and cardiac markers. J Breast Cancer (2012) 0.86
Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis. J Physiol (2015) 0.85
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci U S A (2000) 0.85
A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br J Cancer (2001) 0.85
Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy. J Mol Cell Cardiol (2006) 0.85
Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. Eur J Pharm Biopharm (2013) 0.85
Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. Biomarkers (2009) 0.85
Structure-based DNA-targeting strategies with small molecule ligands for drug discovery. Med Res Rev (2013) 0.84
Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review. Nano Today (2013) 0.84
Hydropathic analysis of the free energy differences in anthracycline antibiotic binding to DNA. Nucleic Acids Res (2003) 0.84
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. Am J Physiol Heart Circ Physiol (2016) 0.83
A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proc Natl Acad Sci U S A (1999) 0.83
In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity. Nutrients (2015) 0.83
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. Br J Pharmacol (2001) 0.83
Promoter-specific inhibition of transcription by daunorubicin in Saccharomyces cerevisiae. Biochem J (2002) 0.82
Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks. Genome Integr (2011) 0.82
CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol (2011) 0.82
Investigation of microdialysis sampling calibration approaches for lipophilic analytes: doxorubicin. J Pharm Biomed Anal (2010) 0.82
Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections. Front Microbiol (2015) 0.82
Prognostic values of filamin-A status for topoisomerase II poison chemotherapy. Int J Biol Sci (2012) 0.81
Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol (2012) 0.81
Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection. Mol Cancer (2013) 0.81
Anthracycline-induced phospholipase A2 inhibition. Cardiovasc Toxicol (2007) 0.81
A new cyano-substituted anthracycline metabolite from Streptomyces sp. HS-NF-1006. J Antibiot (Tokyo) (2016) 0.80
Influence of substituent modifications on the binding of 2-amino-1,8-naphthyridines to cytosine opposite an AP site in DNA duplexes: thermodynamic characterization. Nucleic Acids Res (2009) 0.80
Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage. Mol Cancer Ther (2012) 0.80
CE-LIF method for the separation of anthracyclines: application to protein binding analysis in plasma using ultrafiltration. J Sep Sci (2008) 0.80
Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG). Nucleic Acids Res (1995) 0.79
Radiation sterilization of anthracycline antibiotics in solid state. ScientificWorldJournal (2013) 0.79
p38δ MAPK phenotype: an indicator of chemotherapeutic response in oesophageal squamous cell carcinoma. Anticancer Drugs (2015) 0.79
Anthraquinone G503 induces apoptosis in gastric cancer cells through the mitochondrial pathway. PLoS One (2014) 0.79
N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. Br J Cancer (2004) 0.79
Polyploidy Formation in Doxorubicin-Treated Cancer Cells Can Favor Escape from Senescence. Neoplasia (2015) 0.78
In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Br J Cancer (1995) 0.78
AMP-activated protein kinase α2 and E2F1 transcription factor mediate doxorubicin-induced cytotoxicity by forming a positive signal loop in mouse embryonic fibroblasts and non-carcinoma cells. J Biol Chem (2014) 0.78
Divergent evolution of an atypical S-adenosyl-l-methionine-dependent monooxygenase involved in anthracycline biosynthesis. Proc Natl Acad Sci U S A (2015) 0.78
Tetrahydroanthraquinone Derivative (±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB. J Cancer (2016) 0.78
Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget (2017) 0.77
N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes -- involvement of uncoupling protein UCP2. J Biomed Sci (2014) 0.77
Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific. PLoS One (2012) 0.77
Efficient lytic induction of Kaposi's sarcoma-associated herpesvirus (KSHV) by the anthracyclines. Oncotarget (2014) 0.77
An inulin and doxorubicin conjugate for improving cancer therapy. J Drug Deliv Sci Technol (2013) 0.77
Anticancer efficacy and absorption, distribution, metabolism, and toxicity studies of aspergiolide A in early drug development. Drug Des Devel Ther (2014) 0.77
The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient. Int J Nanomedicine (2014) 0.77
Inherently stealthy and highly tumor-selective gold nanoraspberries for photothermal cancer therapy. Sci Rep (2015) 0.76
Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats. Clin Hypertens (2014) 0.76
Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer. Mol Cancer Res (2016) 0.76
Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip. Mol Pharm (2016) 0.76
Low Intensity Ultrasound Mediated Liposomal Doxorubicin Delivery Using Polymer Microbubbles. Mol Pharm (2015) 0.76
Divergent non-heme iron enzymes in the nogalamycin biosynthetic pathway. Proc Natl Acad Sci U S A (2016) 0.76
Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. Int J Clin Exp Pathol (2015) 0.75
A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats. Iran J Pharm Res (2015) 0.75
Selenorhodamine photosensitizers for photodynamic therapy of P-glycoprotein-expressing cancer cells. J Med Chem (2014) 0.75
Association between DNA methylation and multidrug resistance in human glioma SHG-44 cells. Mol Med Rep (2014) 0.75
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Res (1988) 0.85